LLY

922.39

-1.51%↓

JNJ

186.29

-0.03%↓

UNH

324.11

+0.82%↑

NVS

126.28

-0.09%↓

ABT

126.19

+1.02%↑

LLY

922.39

-1.51%↓

JNJ

186.29

-0.03%↓

UNH

324.11

+0.82%↑

NVS

126.28

-0.09%↓

ABT

126.19

+1.02%↑

LLY

922.39

-1.51%↓

JNJ

186.29

-0.03%↓

UNH

324.11

+0.82%↑

NVS

126.28

-0.09%↓

ABT

126.19

+1.02%↑

LLY

922.39

-1.51%↓

JNJ

186.29

-0.03%↓

UNH

324.11

+0.82%↑

NVS

126.28

-0.09%↓

ABT

126.19

+1.02%↑

LLY

922.39

-1.51%↓

JNJ

186.29

-0.03%↓

UNH

324.11

+0.82%↑

NVS

126.28

-0.09%↓

ABT

126.19

+1.02%↑

Home・Aandelen Lijst・Arrowhead Pharmaceuticals Inc

Arrowhead Pharmaceuticals Inc

Gesloten

SectorGezondheidszorg

39.16 -0.86

Buy Sell

Overzicht

Wijziging aandelenprijs

24u

Huidig

Min

38.67

Max

39.27

Belangrijke statistieken
By Trading Economics
Inkomsten	-547M -179M
Verkoop	-515M 28M
Winstmarge	-643.397
Werknemers	609
EBITDA	-546M -148M

Aanbevelingen
By TipRanks
Aanbevelingen	Buy
12 Maanden Prognose	+13.87% upside

Dividenden
By Dow Jones
Volgende Winsten	25 nov 2025

Marktinformatie
By TradingEconomics
Marktkapitalisatie	3.2B 5.5B
Vorige openingsprijs	40.02
Vorige sluitingsprijs	39.16

Nieuwssentiment

By Acuity

41%

59%

129 / 374 Rangschikking in Healthcare

Technische score

By Trading Central

Vertrouwen

Weak Bearish Evidence

11.5 / 12.23 Steun & Weerstand

Arrowhead Pharmaceuticals Inc Grafiek

Eerdere prestaties zijn geen betrouwbare indicator voor toekomstige resultaten.

Gerelateerd nieuws

9 nov 2025, 21:36 UTC

Winsten

Australia's ANZ Bank Posts 10% Drop in Annual Profit -- Update

9 nov 2025, 21:22 UTC

Winsten

Australia's ANZ Bank Posts 10% Drop in Annual Profit

10 nov 2025, 00:00 UTC

Marktinformatie

India Inflation Poised to Hit New Low -- Market Talk

9 nov 2025, 23:47 UTC

Marktinformatie

Nikkei May Rise on Weaker Yen, Earnings Hopes -- Market Talk

9 nov 2025, 23:35 UTC

Marktinformatie

Gold Edges Higher Amid Signs of U.S. Economic Weakness -- Market Talk

9 nov 2025, 21:05 UTC

Winsten

ANZ FY Total Operating Expenses A$12.88B Vs. A$11.465B Pro Forma>ANZ.AU

9 nov 2025, 21:04 UTC

Winsten

ANZ FY Operating Expenses A$11.85B Ex-Significant Items>ANZ.AU

9 nov 2025, 21:03 UTC

Winsten

ANZ 2H Net Interest Margin 1.54% Vs. 1.56% in 1H>ANZ.AU

9 nov 2025, 20:49 UTC

Winsten

ANZ FY Australia Retail Deposits Up 6% on Year>ANZ.AU

9 nov 2025, 20:49 UTC

Winsten

ANZ FY Australia Home Loan Lending Up 5% on Year>ANZ.AU

9 nov 2025, 20:45 UTC

Winsten

ANZ FY Average Customer Deposits A$760.8B Vs. A$669.4B>ANZ.AU

9 nov 2025, 20:45 UTC

Winsten

ANZ FY Average Gross Loans & Advances A$833.6B Vs. A$733.8B>ANZ.AU

9 nov 2025, 20:42 UTC

Winsten

ANZ FY Results Include Full-Year Benefit of Suncorp Bank Acquisition>ANZ.AU

9 nov 2025, 20:42 UTC

Winsten

ANZ FY Net Interest Margin 1.55% Vs. 1.57%>ANZ.AU

9 nov 2025, 20:41 UTC

Winsten

ANZ FY Common Equity Tier 1 Ratio 12.0% Vs. 12.2%>ANZ.AU

9 nov 2025, 20:41 UTC

Winsten

ANZ FY Net Profit Includes A$1.11B of Notable Items>ANZ.AU

9 nov 2025, 20:39 UTC

Winsten

ANZ FY Credit Impairment Charge A$441M Vs. A$406M>ANZ.AU

9 nov 2025, 20:39 UTC

Winsten

ANZ FY Rev A$22.19B Vs. A$20.55B >ANZ.AU

9 nov 2025, 20:38 UTC

Winsten

ANZ Keeps Dividend at A$0.83 >ANZ.AU

9 nov 2025, 20:38 UTC

Winsten

ANZ FY Cash Profit A$5.79B Vs. A$6.725B>ANZ.AU

9 nov 2025, 20:38 UTC

Winsten

ANZ FY Net A$5.89B Vs. Net A$6.535B >ANZ.AU

8 nov 2025, 13:10 UTC

Acquisities, Fusies, Overnames

Pfizer and Metsera Reach Deal Expected to Top $10 Billion -- Update

8 nov 2025, 03:50 UTC

Acquisities, Fusies, Overnames

Pfizer and Metsera Reach Deal Expected to Top $10 Billion -- 4th Update

8 nov 2025, 03:41 UTC

Acquisities, Fusies, Overnames

Pfizer and Metsera Reach Deal Expected to Top $10 Billion -- WSJ

8 nov 2025, 03:07 UTC

Acquisities, Fusies, Overnames

Pfizer and Metsera Reach Deal Worth Up to $10 Billion -- WSJ

7 nov 2025, 22:36 UTC

Winsten

McDonald's Stock Challenged By a Tougher Economy, Analyst Says. Plus, Marriott, Snowflake, and More. -- Barrons.com

7 nov 2025, 22:22 UTC

Winsten

The Score: GM, Tesla, Palantir, American Airlines and More Stocks That Defined the Week -- WSJ

7 nov 2025, 22:03 UTC

Winsten

Constellation Software 3Q Rev $2.95B >CSU.T

7 nov 2025, 22:03 UTC

Winsten

Constellation Software 3Q Net $210M >CSU.T

7 nov 2025, 22:03 UTC

Winsten

Constellation Software 3Q EPS $9.89 >CSU.T

Peer Vergelijking

Prijswijziging

Arrowhead Pharmaceuticals Inc Prognose

Koersdoel

By TipRanks

13.87% opwaarts potentieel

12 Maanden Prognose

Gemiddelde 44.67 USD 13.87%

Hoogste 80 USD

Laagste 17 USD

Gebaseerd op 8 Wall Street-analisten die 12-maands prijsdoelen bieden voor Arrowhead Pharmaceuticals Inc - Dist. in de afgelopen 3 maanden.

Beoordelingsconsensus

By TipRanks

Buy

8 ratings

Buy

Hold

Sell

Gebaseerd op 8 analisten die aandelenratings hebben gegeven aan Arrowhead Pharmaceuticals Inc - Dist in de afgelopen 3 maanden.

Technische score

By Trading Central

11.5 / 12.23Steun & Weerstand

Recent bearish events outweigh bullish events.

Bearish events outweigh bullish events.

There is one bearish event.

Sentiment

By Acuity

129 / 374 Rangschikking in Gezondheidszorg

Financieel

Verkoop- en administratiekosten

Bedrijfskosten

Winst voor belastingen

Verkoop

Kosten van verkopen

Brutowinst op verkopen

Rente-uitgaven op schulden

EBITDA

Operationele winst

Over Arrowhead Pharmaceuticals Inc

Arrowhead Pharmaceuticals, Inc. develops medicines for the treatment of intractable diseases in the United States. The company's products in pipeline includes Plozasiran, which is in Phase 2b and one Phase 3 clinical trial to treat hypertriglyceridemia, mixed dyslipidemia, and chylomicronemia syndrome; Zodasiran that is in Phase 2b clinical trial for the treatment of dyslipidemia and hypertriglyceridemia; ARO-PNPLA3, which is in Phase 1 clinical trial to treat patients with non-alcoholic steatohepatitis; ARO-RAGE that is in Phase 1/2a clinical trial to treat inflammatory pulmonary conditions; and ARO-MUC5AC, which is in Phase 1/2a clinical trial to treat muco-obstructive pulmonary diseases. It also develops ARO-MMP7 that is in Phase 1/2a clinical trial for treatment of idiopathic pulmonary fibrosis; ARO-DUX4 for the treatment of facioscapulohumeral muscular dystrophy; ARO-SOD1 for the potential treatment of amyotrophic lateral sclerosis; and ARO-C3, which is in Phase 1/2a clinical trial for the treatment of patients with various complement mediated or complement associated renal diseases. In addition, the company is involved in the development of JNJ-3989, which is in Phase 2 clinical trial to treat chronic hepatitis B virus infection; Olpasiran that is in Phase 3 clinical trial to reduce the production of apolipoprotein A; GSK-4532990 that is in phase 2 clinical trial to treat liver diseases; HZN-457, which is in phase 1 clinical trial to treat uncontrolled gout; and Fazirsiran that is in Phase 3 clinical trial for the treatment for liver disease associated with alpha-1 antitrypsin deficiency. Arrowhead Pharmaceuticals, Inc. has license and research collaboration agreements with Janssen Pharmaceuticals, Inc.; Takeda Pharmaceutical Company Limited; Horizon Therapeutics Ireland DAC; Amgen Inc.; and Glaxosmithkline Intellectual Property (No. 3) Limited. The company was founded in 2003 and is headquartered in Pasadena, California.